60 degrees pharmaceuticals expands tafenoquine clinical trial for babesiosis to brigham and women's hospital

The trial (nct06207370) evaluates tafenoquine combined with standard treatment for babesiosis, addressing a critical unmet medical need. the clinical site is led by brigham and women's hospital researchers ann woolley, m.d.
SXTP Ratings Summary
SXTP Quant Ranking